Bee Propolis for Common Cold

Verdict: Weak, inconclusive evidence for the common cold

The evidence that bee propolis treats or prevents the common cold is weak and far from conclusive. A single small oral-spray trial hints it may shorten symptoms by a couple of days, but the overall data are too thin and confounded to recommend it.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This claim lands at a weak (Tier C) grade because the human evidence is sparse and shaky. Only one reasonably designed single-ingredient trial exists: a double-blind RCT of a poplar-type propolis oral spray (PMID 33091857, n=122) in which 83% of users had symptom remission by day 3 versus 28% on placebo, with recovery about two days earlier. But it was industry-affiliated, short (5 days), and used a topical throat spray, so any benefit may be local soothing rather than a true antiviral effect.

The rest of the literature does not close the gap. The largest trial (PMID 14993078, n=430) reported 55% fewer infections in children, but it combined propolis with echinacea and vitamin C, so propolis alone cannot be credited. Two reviews (PMID 34725836; PMID 34979259) note possible antiviral activity yet explicitly state that rigorous randomized trials are lacking, and an earlier review (PMID 27366357) rated the underlying studies as low quality. There is no Cochrane review or pooled meta-analysis.

Regulators and clinics reinforce caution. The US FDA has issued warning letters treating propolis throat-spray cold and antiviral claims as unapproved drug claims, and the EU's EFSA rejected all propolis-related health claims. Cleveland Clinic is skeptical, while the NHS, WHO, Mayo Clinic, and NIH offer no endorsement. Propolis is also a documented allergen for people sensitive to bee products, so it is published only with a warning rather than as an effective remedy.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
84%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.46
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, p…
PMID: 33091857 2021 RCT (double-blind) n = 122
Finding: After 3 days, 83% of propolis subjects had symptom remission vs 28% of placebo (placebo group: 72% still had >=1 symptom). All recovered by day 5. Resolution occurred ~2 days earlier in propolis group.
⚠️ Industry-funded Effect size: Symptom remission ~2 days earlier than placebo; no serious adverse events
View on PubMed
The antiviral and immunomodulatory activities of propolis: An update and future perspectives for respiratory diseases (Magnavacca et al.)
PMID: 34725836 2022 Other
Finding: Preclinical data support antiviral activity against respiratory viruses (influenza, rhinovirus, RSV, SARS-CoV-2); clinical evidence remains limited and authors explicitly note 「the lack of rigorous randomized clinical trials in the context of respiratory diseases is tangible」.
Academic Effect size: qualitative; no pooled effect
View on PubMed
The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review (Zulhendri et al., Biomedicine & Pharmacotherapy)
PMID: 34979259 2022 Other
Finding: Concluded propolis 「may be effective」 as primary or adjunctive therapy for respiratory tract diseases (including URTI, sinusitis, pharyngitis) based on weight of evidence, but called for larger RCTs; heterogeneity of propolis composition flagged as major limitation.
Effect size: qualitative
View on PubMed
Effectiveness of an Herbal Preparation Containing Echinacea, Propolis, and Vitamin C in Preventing Respiratory Tract Infections in Children (Cohen HA et al., Arch Pediatr Adolesc Med)
PMID: 14993078 2004 RCT (double-blind) n = 430
Finding: Significant reduction in number of illness episodes (55% reduction) and days with fever vs placebo; effect cannot be attributed to propolis alone due to multi-ingredient formulation.
⚠️ Industry-funded Effect size: 55% fewer URTI episodes (combination product)
View on PubMed
The consumption of propolis and royal jelly in preventing upper respiratory tract infections and as dietary supplementation in children (Yuksel & Akyol)
PMID: 27366357 2016 Other
Finding: Reviewed evidence that bee products show preventive potential against pediatric URTI; quality of underlying trials judged low to moderate; no pooled effect.
🟠 Limited quality Effect size: qualitative
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Propolis is proven to have distinct antibacterial, antiviral and antifungal properties... [Propolis & Herb Throat Spray] A quick, effective way to soothe sore, dry scratchy throats — cited by FDA as causing products to be unapproved new drugs source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
蜂膠之多環芳香族碳氫化合物(PAH4,即苯(a)駢芘 BaP、苯(a)駢蒽 BaA、苯(b)駢苯并芴 BbF、䓛 Chr 之總和)限量為 50 ppb(μg/kg)以下。 source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-common-cold-INT-bee-propolis-001 繁體中文版 →